Omniscient Neurotechnology launches Quicktome brain-mapping platform following FDA clearance

Omniscient Neurotechnology has received US Food and Drug Administration (FDA) 510(k) clearance for Quicktome—a digital brain-mapping platform that allows neurosurgeons to visualise and understand a patient’s brain networks prior to performing life-changing brain surgery. In addition to FDA clearance in the USA, Quicktome has also received Health Canada approval as well as regulatory clearance by the Therapeutic Goods Administration (TGA) of Australia.

“I wish I had technology like this when I started practicing,” said Michael Sughrue, a neurosurgeon who has completed more than 3,000 brain tumour removals, and is also chief medical officer at Omniscient. “When I learnt about connectomics, I realised the biggest impact I could make to the field of neurosurgery was to make Quicktome a routine source of insight for all neurosurgeons. With this groundbreaking technology, our hope is for a better quality of life for patients and families after brain surgery.”

Quicktome is a neurosurgical planning software that incorporates “connectomics”, the field of understanding brain connectivity, into routine neurosurgical planning. Critically, by visualising networks that are responsible for complex functions such as language, movement, and cognition, Quicktome assists neurosurgeons in making more informed decisions and reduces surgical uncertainty, an Omniscient press release states.

Utilising cloud computing for large-volume data processing, and intuitive browser-based interfaces, Quicktome aims to streamline these processes for neurosurgeons. The digital platform also enables multidisciplinary collaboration in hospitals, and greater insight on a patient before and during surgery, the release adds.

“We are thrilled to receive regulatory clearance for Quicktome,” said Omniscient CEO Stephen Scheeler. “This is the first digital mapping platform designed to incorporate brain connectome data for neurosurgeons to improve patient outcomes. Until now, the tools that neurosurgeons have relied on have been no match for the brain’s complexity. Quicktome breaks information down into actionable insights to inform the impact each incision will have on the patient.

“Since its authorisation, physicians are already relying on this technology to guide surgical planning, Scheeler continued. “This is a significant milestone for Omniscient and, more importantly, begins a new era for neurosurgery for patients and physicians.”

Original Article: (https://neuronewsinternational.com/omniscient-neurotechnology-quicktome-brain-mapping-platform-fda-clearance/)